Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

BACKGROUND: To determine safety and efficacy of single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab in stage III-IVB head and neck cancer. METHODS: Patients received a single cycle of cisplatin 30 mg/m² on days 1–3 and docetaxel 75 mg/m² on day 1 combined with durva...

Descripción completa

Detalles Bibliográficos
Autores principales: Hecht, Markus, Gostian, Antoniu Oreste, Eckstein, Markus, Rutzner, Sandra, von der Grün, Jens, Illmer, Thomas, Hautmann, Matthias G, Klautke, Gunther, Laban, Simon, Brunner, Thomas, Hinke, Axel, Becker, Ina, Frey, Benjamin, Semrau, Sabine, Geppert, Carol I, Hartmann, Arndt, Balermpas, Panagiotis, Budach, Wilfried, Gaipl, Udo S, Iro, Heinrich, Fietkau, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539609/
https://www.ncbi.nlm.nih.gov/pubmed/33023982
http://dx.doi.org/10.1136/jitc-2020-001378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539609/
https://www.ncbi.nlm.nih.gov/pubmed/33023982
http://dx.doi.org/10.1136/jitc-2020-001378

Ejemplares similares